Three States Challenge Trump DOJ Over Cannabis Rescheduling Process
State governments file federal lawsuit claiming DOJ violated procedural requirements in marijuana classification review, threatening industry reform timeline.
Three state governments have filed a federal lawsuit against the Trump administration's Department of Justice, alleging procedural violations in the ongoing marijuana rescheduling process. The legal challenge targets what the states characterize as unlawful administrative actions that bypass required regulatory protocols for controlled substance classification changes.
The lawsuit creates additional uncertainty for cannabis operators already navigating a complex regulatory transition. Multi-state operators like Curaleaf Holdings (CURLF), Green Thumb Industries (GTBIF), and Trulieve Cannabis (TCNNF) face continued operational challenges as the rescheduling timeline extends. These companies currently operate under state-legal frameworks while remaining federally prohibited, limiting access to traditional banking services and standard business tax deductions.
The legal action highlights the fractured approach to cannabis policy between federal and state jurisdictions. Currently, 38 states have legalized medical marijuana programs, while 21 states permit adult-use sales. This patchwork creates compliance burdens for operators and limits interstate commerce opportunities that could drive industry consolidation and efficiency gains.
Rescheduling marijuana from Schedule I to Schedule III would provide immediate tax relief through Section 280E elimination, potentially improving margins across the sector by 20-40%. However, the legal challenge introduces timing risks for operators banking on near-term regulatory relief. Companies with heavy tax burdens, particularly those in mature markets like California and Colorado, would benefit most from swift resolution.
The cannabis industry's institutional investment appeal remains constrained by federal prohibition, with many institutional funds avoiding exposure due to compliance concerns. Resolution of the rescheduling process, regardless of outcome, would provide clarity for capital allocation decisions. The lawsuit underscores the political volatility surrounding cannabis policy, reinforcing the sector's regulatory risk premium that continues to weigh on valuations across public operators.